Multicenter validation of an RNA-based assay to predict anti-PD-1 disease control in patients with recurrent or metastatic head and neck squamous cell carcinoma: the PREDAPT studyKevin C. Flanagan, Eric J. Duncavage, Jon Earls et al.|Journal for ImmunoTherapy of Cancer|2024Cited by 9
Patient‐Reported Swallowing Outcomes in HPV+ Oropharyngeal Cancer by Postoperative Chemoradiation Dose in MINT and E3311Theresa Tharakan, Ryan S. Jackson, Sidharth V. Puram et al.|Otolaryngology|2025Cited by 2
675 Safety and tolerability of magrolimab combination therapy in patients with recurrent or metastatic head and neck squamous cell carcinoma (RM-HNSCC)A. Dimitrios Colevas, Douglas Adkins, Katie Kerrigan et al.|Regular and Young Investigator Award Abstracts|2023Cited by 1
Safety and Tolerability of Magrolimab Combination Therapy in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (RM-HNSCC)A. Dimitrios Colevas, Douglas Adkins, Michael F. Howland et al.|International Journal of Radiation Oncology*Biology*Physics|2024Cited by 1
Palbociclib (PAL) + cetuximab (CET) vs CET in patients (pts) with head and neck cancer: Asian subgroup analysisMakoto Tahara, Douglas Adkins, Jin Lin et al.|Annals of Oncology|2019Cited by 0